. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: Expert Opin Biol Ther. 2020 Jan 20;20(3):305–317. doi: 10.1080/14712598.2020.1713085

Table 1.

Molecular alterations in glioma.

_{Genetic Lesions}╲^{Histopathology}	WHO Grade II and III		WHO Grade IV
_{Genetic Lesions}╲^{Histopathology}	Oligodendroglioma	Astrocytoma	Glioblastoma
IDH1	Mutated (82%)	Mutated (68%)	Mutated (7%)
1p/19q	Co-deleted (70%)	Retained	Retained
ATRX	Mutated (19%)	Mutated (48%)	Mutated (7%)
P53	Mutated (24%)	Mutated (65%)	Mutated (30%)
CDKN2A	Deletion (2%)	Deletion (22%)	Deletion (54%)
RTK Pathway	EGFR Amp/Mut (5%) PTEN Del/Mut (2%) PDGFRA Amp/Mut (4%)	EGFR Amp/Mut (5%) PTEN Del/Mut (2%) PDGFRA Amp/Mut (4%)	EGFR Amp/Mut (64%) PTEN Del/Mut (38%) PDGFRA Amp/Mut (16%)